SCHEMBL4969208

SCHEMBL4969208

CN1CCC(c2ccc(Cl)cc2F)CC1

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 5/20 0.64
DRD4 P21917 2/20 0.43
LSS P48449 1/20 0.43
APP P05067 1/20 0.43
DRD2 P14416 1/20 0.43
POLB P06746 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
NOS3 P29474 2/20 0.42
NOS1 P29475 2/20 0.42
NOS2 P35228 2/20 0.42
GRM2 Q14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1824551 0.90 OPRL1 (0.58) OPRL1PROKR1HTR2CHTR2B
SCHEMBL433273 0.84 OPRL1 (0.59) OPRL1PROKR1HTR2AHTR2CHTR2B
SCHEMBL4975027 0.83 GRM2 (0.47) OPRL1APPDRD2GRM2
SCHEMBL4969638 0.83 OPRL1 (0.47) OPRL1DRD4LSSDRD2POLB
SCHEMBL4976022 0.81 OPRL1 (0.47) OPRL1DRD2HTR2CHTR2B
SCHEMBL14924438 0.81 OPRL1 (0.46) OPRL1DRD4APP
SCHEMBL434518 0.80 OPRL1 (0.56) OPRL1PROKR1HTR2AHTR2CHTR2B
SCHEMBL433558 0.80 OPRL1 (0.60) OPRL1PROKR1HTR2AHTR2CHTR2B
SCHEMBL24310184 0.80 CYP1A2 (0.55) OPRL1APPDRD2
SCHEMBL28506116 0.80 KDM1A (0.47) OPRL1APPNOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963268-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Neurosearch Sweden AB (SE) 2008-09-03 EP claimed
WO-2007065655-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NEUROSEARCH SWEDEN AB (SE) 2007-06-14 WO claimed
US-20080269286-A1 Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2008-10-30 US disclosed
EP-1963268-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Neurosearch Sweden AB (SE) 2008-09-03 EP disclosed
WO-2007065655-A1 DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NEUROSEARCH SWEDEN AB (SE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269286-A1 Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission SLC6A2, SLC18A2, PNMT OPRL1 30/4885DRD4 87/4885LSS 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.